INTRODUCTION
The y-aminobutyric acidA (GABAA) receptor of mammalian brain is a member of the ligand-gated ion-channel superfamily (Schofield et al., 1987) . It is a chloride-ion channel that is gated by the major inhibitory neurotransmitter GABA and it has been shown to contain multiple allosteric drug-binding sites for therapeutically important compounds, notably the anxiolytic benzodiazepines and the depressant barbiturates. The GABAA receptor is an integral membrane glycoprotein with a heterologous oligomeric structure. It has been purified to apparent homogeneity from several vertebrate species by benzodiazepine affinity chromatography and it was shown to consist of two polypeptide chains, a with Mr 53000 and /, with Mr 58000 (reviewed by Stephenson, 1988) . The primary structures of the al and the , polypeptides have been deduced by molecular cloning (Schofield et al., 1987) . The subunits are similar in sequence not only to each other (-35 % amino acid sequence identity; -55 similarity), but to other members of the superfamily, which include the nicotinic acetylcholine receptor and the glycine receptor (Schofield et al., 1987) . This led to a proposed model of the GABAA receptor with a large extracellular hydrophilic N-terminal domain, four transmembrane hydrophobic domains, M1-M4, with the C-termini of both subunits located extracellularly and the large hydrophilic loop between M3 and M4 being intracellular (Schofield et al., 1987) .
The locations of the various drug-binding domains within the receptor structure are not known. It is known, however, that the benzodiazepipe [3H]flunitrazepam specifically photoaffinity-labels the a-subunit with Mr 53000 in brain membranes (e.g. Mohler et al., 1980) and in purified receptor preparations (e.g. Sigel et al., 1983) . Czajkowski & Farb (1986) showed that the benzodiazepine recognition site is orientated towards the extracellular space by carrying out the photoaffinitylabelling reaction in chick neuronal cells and showing that this reaction was competitively blocked by the positively charged benzodiazepine Ro 7-0213. Ro 7-0213 is non-membrane-permeable (Czajkowski & Farb, 1986) . Also, limited tryptic-digestion studies of photoaffinitylabelled rat and chick brain membrane preparations have shown that a fragment of Mr 24000-27000 remains anchored in the membrane (Klotz et al., 1984; Eichinger & Sieghart, 1985; Czajkowski & Farb, 1986; Czajkowski et al., 1989) . Treatment with higher concentrations of trypsin resulted in the appearance of a 6000-Mr fragment into the supernatant (Klotz et al., 1984) . Since the orientation of the receptor in the membranes at this time is predicted and not yet established, these experiments are of limited value for interpretation, even with the knowledge of the primary structure of the a-subunit.
In order to overcome these problems, we have adopted the approach of photoaffinity-labelling the purified receptor with [3H] flunitrazepam and subjecting this material to defined chemical cleavage with CNBr. The products of the reaction are identified with GABAAreceptor-sequence-specific antibodies. This approach is of value for the study of rare proteins because it is difficult to purify them in sufficient amounts for amino acid microsequencing and also, particularly in the case of the GABAA receptor peptides, isolation to homogeneity is complicated by the existence of multiple subunit isoforms (Levitan et al., 1988; Pritchett et al., 1988a Hoffman-La Roche, Basel, Switzerland, and clorazepate was a gift from Boehringer Ingelheim, Bracknell, Berks., U.K. The anti-(GABAA-receptor sequence)-specific antibodies used were as previously described Stephenson et al., 1989) , and all other materials were as noted elsewhere (Sigel et al., 1983; Stephenson et al., 1986a) .
Preparation of purified GABAA receptor
The GABAA receptor was purified from adult bovine cerebral cortex by the sodium deoxycholate/Triton X-100 benzodiazepine affinity-chromatography method as described previously (Sigel et al., 1983 ).
Photoaffinity-labelling and CNBr cleavage of the purified GABAA receptor
The purified GABAA receptor was photoaffinity labelled with [3H]flunitrazepam as described previously (Sigel et al., 1983; Stephenson et al., 1986b incubated on ice for 60 min. Samples were irradiated at 254 or 366 nm for three 15 min periods with 5 min intervals between successive irradiations to prevent overheating, at 6 cm distance at 4°C with shaking. Excess unlabelled flunitrazepam (10-5 M final concn.) was added and samples were further incubated in the dark for 60 min. Non-specific incorporation of radioactivity was determined by carrying out the photoaffinity-labelling reaction in the presence ofnon-radioactive flunitrazepam.
The photoaffinity-labelled receptor was precipitated by the addition of an equal volume of 24 % (w/v) trichloroacetic acid. Samples were incubated on ice for 15 min, centrifuged (10000 g, 15 min) and the supernatant discarded. The protein pellets were further washed with 12 % (w/v) tricholoroacetic acid and twice with acetone. Aliquots of the photoaffinity-labelled purified GABAA receptor were precipitated and washed and either subjected to SDS/PAGE under reducing conditions followed by fluorography to show the specificity of photoaffinity labelling of the intact receptor or they were counted for radioactivity to determine the efficiency of the photolabelling reaction. In the latter case, the protein pellets were counted for radioactivity to determine specific irreversible incorporation.
CNBr cleavage of the photoaffinity-labelled receptor was carried out according to the method of Gross (1967 The purified GABAA receptor and the CNBr cleavage products were analysed by SDS/PAGE under reducing conditions in either 12 %-(w/v)-polyacrylamide slab gels or 15.5-20 %-polyacrylamide-gradient slab gels. Proteins were stained by the silver-stain method as described previously (Mamalaki et al., 1987) , and radioactivity was determined by immersion of the gel in Autofluor (National Diagnostics), followed by gel drying and exposure to pre-flashed Fuji X-ray film at -80 'C. Mr values of peptides in gradient gels were calculated from standard calibration curves of log Mr versus acrylamide monomer concentration (%). Alternatively, samples were transferred to nitrocellulose membranes and Western blotting was carried out as previously described (Stephenson et al., 1986a; and Stephenson et al. (1989) . Radioactivity was determined either by scanning on a Berthold t.l.c. linear analyser or by immersion in Autofluor, drying and exposure to pre-flashed Fuji X-ray film as described above. Biotinylated concanavalin A overlay Protein and peptides were transferred to nitrocellulose as for Western blotting, except that the transfer buffer contained 0.1 % (w/v) SDS. The nitrocellulose was rinsed superficially with 50 mM-Tris/HCl, pH 7.4, containing 0.9 % (w/v) NaCl for 10 min at room temperature. It was quenched by incubation with 2 % (w/v) polyvinylpyrrolidone in 50 mM-Tris/HCl, pH 7.4, containing 0.9 % (w/v) NaCl, 5 mM-MgCl2 and 1.5 mM-CaCl2 for 1 h at 37 'C. The nitrocellulose was incubated with biotinylated concanavalin A (10 ug/ml) in 50 mM-Tris/HCl, pH 7.4, containing 0.9 % (w/v) NaCl and 2 % (w/v) polyvinylpyrrolidone for 60 min at room temperature. Blots were washed with four changes of 50 mM-Tris/HCl, pH 7.4, containing 0.9 % (w/v) NaCl, 2 % (w/v) polyvinylpyrrolidone and 0.2 % Tween at room temperature over a period of 20 min.
The Vectastain ABC reagent was prepared according to the manufacturer's instructions and then incubated for 45 min at room temperature with the nitrocellulose (5 ml). The nitrocellulose was washed with 50 mM-Tris/ HCI, 0.9 % (w/v) NaCl, 2 % (w/v) polyvinylpyrrolidone and 0.1 % Tween as described above, and then developed.
The developing solution was physiological buffered saline (5 ml), containing diaminobenzidine (100,l of a 40 mg/ml stock solution), NiCl2 (25,u of an 80 mg/ml stock solution) and 3 % (v/v) H202 (15,1). The specificity of the reaction was controlled by carrying out the reaction with biotinylated concanavalin A in the presence of 0.2 M-cx-methyl mannoside. After development, the nitrocellulose membranes were immersed in Autofluor, dried and exposed to pre-flashed X-ray film.
RESULTS

Photoaffinity labelling of the purified GABAA receptor
In accord with previous observations, it was fically and irreversibly incorporacied into the purified GABAA receptor. It was found that 20.4+9% (n = 11 independent receptor preparations) of (Fig. 2) .
CNBr cleavage of the purified photoaffinity-labelied GABAA receptor Silver-stain SDS/PAGE in gradient gels of the photoaffinity-labelled purified GABAA receptor after CNBr cleavage gave a characteristic pattern (Fig. 3) . Notably, the a-and f-subunits of the receptor were completely cleaved to lower-Mr species; there was a CNBr cleavage product at Mr 33 000 and several peptides with Mr values in the range 26 000-3000. Radioactive scanning or fluorography of the CNBr cleavage products showed that the radioactivity was incorporated into a broad peptide band of Mr 11 711 + 1334 (n = 6), where n refers to the variation between gels for one receptor preparation (Figs.  1 and 3) . The sizes of CNBr radioactive fragments from independent receptor preparations were in the range Mr 8000-12000. Control samples were either purified receptor photolabelled with [3H]flunitrazepam in the presence of 10-5 M-flunitrazepam for the determination of non-specific incorporation of radioactivity or purified native receptor. For the former, there was no incorporation of radioactivity into the a-subunit and no radioactivity present in the CNBr cleavage products (results not shown). When the purified non-photolabelled receptor was subjected to CNBr cleavage followed by SDS/PAGE in gradient gels, the pattern of silver staining was found to be identical with that for [3H]flunitrazepamlabelled material (results not shown). Immunoreactivity of CNBr cleavage products of purified GABAA receptor
The CNBr cleavage products were also tested for their reactivity with anti-(GABAA-receptor sequence-specific)
antibodies. It was found that anti-[cl-(1-15)-peptide] antibodies recognized two peptide fragments of Mr 15293+1372 (n = 7) and 14166+1894 (n = 7) (Fig. 1) .
The anti-[al-(324-341)-peptide] antibodies recognized five peptide fragments of Mr 32000, 30000, 22000, 18000 and 12000 (Fig. 1) . Anti-[al-(413-429)-peptide] antibodies also recognized five peptide fragments of Mr 32000, 29000, 20000, 17000 and 11000 (Fig. 1) . In all experiments the immunoblotting was carried out by using photoaffinity-labelled GABAA receptor and, after development of the blot, it was exposed to X-ray film. In each case, the radioactivity was clearly separated from the immunoreactive bands (Fig. 1) .
In some experiments it was evident that the CNBr cleavage reaction had not gone to completion, because both silver-staining SDS/PAGE and fluorography revealed the presence of a-subunit together with cleavage products with Mr values higher than those observed previously. These partial CNBr digests were analysed for radioactivity and immunoreactivity with the sequencespecific antibodies in both SDS/PAGE gradient gels and 12 %-polyacrylamide gels for higher resolution. Firstly, on SDS/ 12 %-PAGE, it appeared that the non-digested al-subunit migrated as a doublet, with the heavier staining band having an apparently higher Mr than the non-digested control al1-subunit. This was the case for all three specific anti-al antibodies. The anti-[al-(1-l5)-peptide] recognized seven bands with corresponding Mr 47000,44000,42000,40000,34000,27000 and 25000 as calibrated on SDS/ 12 %-PAGE gels (Figs. 1 and 2) . : i i i A -. . j : a n ::; :j .:
, , . : : : i . i . . i : . . CNBr digestion peptides of 13Hjflunitrazepam-photoaffinity-labelled purified GABAA receptor in SDS/12%-PAGE The purified GABAA receptor was photoaffinity-labelled with [3H]flunitrazepam and subjected to complete and limited CNBr chemical cleavage. The resultant peptides were dissolved in SDS/PAGE sample buffer and subjected to SDS/PAGE under reducing conditions in 12 %-polyacrylamide slab gels. The peptides were transferred to nitrocellulose membranes and probed with biotinylated concanavalin A as described in the Experimental section. After development, the membranes were incubated in Autofluor and exposed to X-ray film at -80 'C. Lane precluded their unambiguous assignment with the radioactive peptides seen after fluorography. In the present paper we have described studies in which we have begun to map the site of benzodiazepine photoaffinity labelling within the GABAA-receptor structure. The strategy that we have adopted is the use of CNBr chemical cleavage of the purified [3H]flunitrazepam-photoaffinity-labelled receptor. The reasons for this were twofold. First, CNBr cleaves specifically at the C-terminal end of methionine residues, and the number of methionine residues in the al subunit is 12; thus both the number of peptide fragments is low and their predicted sizes (Fig. 6 ) make them amenable to study by SDS/PAGE. Secondly, the cleavage method is a chemical one, and thus it circumvents any problems that may be incurred in the further purification of these peptides, as would be the case with proteolytic methods.
We have shown that, for the intact receptor, after [3H]flunitrazepam photoaffinity-labelling, the radioactivity is coincident in two SDS/PAGE systems with the subunit labelled with three GABAA-receptor a l-subunitspecific antibodies. Complete CNBr cleavage, defined by the complete disappearance of a-subunit, gave a radioactive peptide of Mr 12000, a doublet with Mr 15000 and 14000, which was recognized by anti-[alI -(1-1 5)-peptide] antibodies and five peptide fragments of Mr 32000, 30000, 22000, 18000 and 12000, which were recognized by both anti-[al-(324-341)-peptide] and anti-[al-(413-429)-peptide] antibodies. Since there is no methionine between the sequences al 324-341 and al 413-429, antibodies against these peptides recognize the same chemical cleavage products. Thus the peptide of Mr 14000 must correspond to the al protein sequence 1-58 and the C-terminal CNBr cleavage products to al 287-429 (12000), al 267-429 (18000), al 237-429 (22000), al 214-429 (30000) and al 49-429 (Table 1 and Fig. 6 ). The Mr-15 000 peptide may correspond to al 1-81, although it is possible that the peptide recognized by the anti-[al-(1-15)-peptide] antibody is the a2 1-58 subunit sequence, since it has been pointed out that there are several amino acid identities in the sequences a.l 1-15 and a2 1-15 which may be sufficient to cause immunocross-reactivity between subunits . The a-subunit is known to be N-glycosylated, and it has been shown that treatment of the purified GABAA receptor with endoglycosidase F results in a decrease in the Mr of the a-subunit of 9000 (Mamalaki et al., 1987) .
M, values for the predicted CNBr cleavage products were calculated from the deduced primary structure of the alsubunit and are given to two significant figures. In the calculation it was assumed that the 9000 Mr contribution of the carbohydrate of the acl-subunit (Mamalaki et al., 1987 ) is attached at threonine-13.
Predicted
Predicted peptide peptide sequence 10-3 X Mr sequence 10-3 X Mr When account is taken of the contribution by weight of the carbohydrate moieties to the peptides, there is good agreement between the sizes of the CNBr fragments predicted from the primary structure of the al-subunit and the experimental results (Table 1 and Fig. 6 ). (It was assumed in these calculations that most of the carbohydrate was attached at threonine-13; see below.) Since the peak of radioactivity did not correspond to any of the immunoreactive peptides, it must lie within the amino acid sequence al 58-148 or be associated with the y2-subunit (Pritchett et al., 1988a (Pritchett et al., , 1989 3 months with the Mr47 000, -44000, -42000, -40000 and -34000 peptides, which indicates that it may be associated with the al 1-148 sequence, although the possibility that the radioactivity is associated with peptides derived from the y2-subunit cannot be ruled out (see below). For the reactivity of the anti- [al-(413-429) -peptide] antibodies with the partial CNBr digestion, radioactivity was associated with the al-(59-429)-peptide, but beyond that the resolution was lost.
Further substantiation of the identification of the peptides was obtained by their ability to react specifically with biotinylated concanavalin A. In all experiments, for the complete CNBr digestion, there were two strongly reactive peptides with Mr values of 15000 and 14000. These were identical with the pair of peptides recognized by the anti-[al-(1-15)-peptide] antibodies and thus must correspond to the al 1-58 amino acid sequence. This contains one consensus glycosylation sequence at threonine-13 and thus confirms the identity of this peptide and, because the signal was strong, we suggest that it contains most of the carbohydrate, as predicted from the endoglycosidase experiments (Mamalaki et al., 1987) . There are two other consensus glycosylation sequences within the al-subunit. Threonine-340, with the current receptor model, is in the cytoplasmic loop domain, and it is assumed that it is not glycosylated; threonine-113 is extracellular, but under the conditions of complete chemical cleavage, it will be too small for the SDS/PAGE system employed here, i.e. two amino acids. For the partial cleavage, a multiplicity of reactive products were seen. It should be noted that, in this case, reactivity with all subunit isoforms present will be found, and the results are difficult to interpret. Nevertheless, the pattern of distribution of glycopeptides followed most closely the anti-[al-(1-15)-peptide] immunoreactive peptides. The al-subunit is the most prevalent of the GABAA receptor polypeptides .
The Mr of the radioactive CNBr-cleaved material is in the range 8000-12000, which would correspond to a sequence of approx. 80-100 amino acid residues. Within the sequence al 59-148 there are six methionine residues, which, if cleavage occurred at all of these, would give rise to peptides with Mr values less than 10000. It is possible that, in the purified receptor, these methionine residues are oxidized and therefore not reactive with CNBr. Alternatively, it may be that the Mr of the photoaffinity-labelled peptide is overestimated in the SDS/PAGE system employed. It is proven, however, that the site is not contained in the sequences of the alsubunit 1-58 and 148-429.
It has been reported that a histidine residue is important for agonist benzodiazepine binding. Treatment of both membrane-bound receptor (Burch & Ticku, 1981; Lambolez & Rossier, 1987) and purified GABAA receptor (Duggan & Stephenson, 1987) with the histidine modifying reagent, diethyl pyrocarbonate, resulted in the specific loss of benzodiazepine-binding sites. This inactivation was prevented by preincubation with unlabelled benzodiazepine agonists and reversed by treatment with hydroxylamine. Although it is not requisite that this histidine residue should lie within the sequence of the al-subunit, i.e. al 59-148, which has not been excluded from containing the site of photoaffinity labelling, it is notable that there are three histidine residues in this region at residues 102, 110 and 142. Each of these histidine residues is conserved in the a2-and a3-subunit isoforms of the receptor. The al-and the a3-subunits have been shown to be photoaffinity-labelled with benzodiazepines (Kirkness & Turner, 1988) .
It was reported that when the GABAA-receptor bovine a-and fl-subunits were expressed in Xenopus oocytes (Levitan el al., 1988) or the corresponding human subunits in transfected cells (Pritchett et al., 1988a) GABA-gated chloride-ion fluxes, which were potentiated by barbiturates but not by benzodiazepines, were formed.
Recently, however, a novel subunit (y2) has been identified (by homology hybridization) from human foetal brain that confers both benzodiazepine-sensitivity on GABAA-gated channels and the detection of specific benzodiazepine-binding activity to receptors in cells transiently transfected with a-, ,-and y2-subunit cDNAs (Pritchett et al., 1988b (Pritchett et al., , 1989 . The y2-subunit is related in sequence to the a-and fl-subunits to the extent of 30-40 % amino acid identity; it has a predicted Mr of 49 800 and three potential sites for N-glycosylation. If the y2-subunit is present in the bovine GABAA receptor and it is photoaffinity-labelled with [3H]flunitrazepam, it would be predicted to be indistinguishable from the labelled al-subunit on one-dimensional SDS/PAGE. There are several points to be made with regard to the role of the y2 subunit in benzodiazepine binding. First, the y2-subunit cDNAs can form GABAA-gated channels which are potentiated by barbiturates when expressed singly in cells, but benzodiazepine potentiation and binding was found only with the co-expression of al-, fiand y2-subunit cDNAs (Pritchett et al., 1988a (Pritchett et al., , 1989 subunits. These subunits correspond in Mr to the acI-and the a3-polypeptides as identified with isoform-specific antibodies . Thirdly, we have shown that anti-[al-(324-341)-peptide] antibodies specifically immunoprecipitate radioactivity from denatured benzodiazepine-photoaffinity-labelled purified preparations (F. A. Stephenson & M. J. Duggan, unpublished work) . Thus these observations all support an integral role of the al-and the y2-subunits in benzodiazepine binding. In the studies that we have described here, we have used antibodies to amino acid sequences which are not conserved between the al-and the y2-polypeptides, and thus the finding that, after complete CNBr cleavage, the agonist benzodiazepine-photoaffinity-labelling site does not lie within the sequences al 1-58 and al 146-429 is valid. For the partial-CNBr-cleavage experiments, however, although the radioactivity in the peptide fragments is coincident with the peptides recognized by the anti-(al-subunit) antibody, we cannot exclude the possibility that the radioactivity is associated with y2-subunit CNBr products, since the distribution of methionine residues in the y2-subunit would predict a limited cleavage pattern similar to that obtained for the al-subunit with respect to Mr (Pritchett et al., 1989) . Further studies using anti-(y2-subunit) antibodies are required to answer the questions concerning the roles of the acl-and the y2-polypeptides in the formation of the benzodiazepinebinding site. 
